A synthetic peptide acting as a triple agonist for GLP-1, GIP, and glucagon receptors, designed for treating obesity and type 2 diabetes by promoting weight loss and glycemic control.
Yin. Yue Y; Zhang. Minghan M; Cao. Qiuyu Q; Lin. Lin L; Lu. Jieli J; Bi. Yufang Y; Chen. Yuhong Y
A big review of 29 trials found that drugs that act like GLP‑1 (including the newer peptide retatrutide) cut heart‑related events and improve blood pressure, weight, cholesterol and inflammation in overweight people who don’t have diabetes. This means you can get heart‑health and weight‑loss benefits from these drugs even if you’re not diabetic.
Goldney. Jonathan J; Hamza. Malak M; Surti. Farhaana F; Davies. Melanie J MJ; Papamargaritis. Dimitr...
Retatrutide is a new triple‑agonist drug that hits GLP‑1, GIP, and glucagon receptors. In early trials it caused massive weight loss – up to 24% in people with obesity and about 17% in those with type‑2 diabetes – and dramatically lowered blood sugar, blood pressure, cholesterol, waist size, and liver fat. The main side effects were typical gut upset, and no serious safety issues showed up yet.
Retatrutide is a new peptide that hits three hormone receptors (GLP‑1, GIP, and glucagon) and has shown big weight‑loss numbers in early trials – about 17% loss after 6 months and 24% after a year – while also being studied for diabetes and fatty liver. It’s still in Phase III, so it isn’t on the market yet, but the early data suggest it could become a powerful tool for cutting fat and improving metabolic health.
The paper explains that the biggest weight‑loss success comes from bariatric surgery, which works partly by changing gut hormones. New drugs that combine GLP‑1, GIP, and glucagon signals (like retatrutide) can cause weight loss almost as big as surgery, opening the door to a non‑surgical "medical bypass" for obesity and related health problems.
Jastreboff. Ania M AM; Kaplan. Lee M LM; Frías. Juan P JP; Wu. Qiwei Q; Du. Yu Y; Gurbuz. Sirel...
In a 48‑week trial, the triple‑hormone peptide retatrutide helped people with obesity lose a lot of weight – up to about 24% of body weight at the highest dose. The weight loss got bigger with higher doses, and most people on the 4‑8‑12 mg doses lost at least 10% of their weight. The main side effects were stomach‑related issues that got milder when the dose started lower, and there was a temporary rise in heart rate.
Rosenstock. Julio J; Frias. Juan J; Jastreboff. Ania M AM; Du. Yu Y; Lou. Jitong J; Gurbuz. Sirel S;...
In a phase‑2 trial, the experimental peptide retatrutide (which hits GIP, GLP‑1 and glucagon receptors) lowered blood sugar by up to 2 % and cut body weight by about 17 % after 36 weeks in people with type‑2 diabetes. The biggest effects were seen at the higher doses (8‑12 mg), and side‑effects were mainly mild stomach upset, similar to other GLP‑1 drugs.
Abburi. Kaivalya K; Melson. Eka E; Miras. Alexander D AD; Papamargaritis. Dimitris D
A new drug combo called retatrutide, which hits three gut hormones (GLP‑1, GIP, and glucagon), is showing weight‑loss results that are almost as good as bariatric surgery. This is part of a wave of next‑generation obesity pills that go beyond the single‑hormone drugs we already have.
Retatrutide, a new anti‑obesity peptide, cut body weight by about 22% compared with placebo and slashed liver fat by roughly 80% in adult trials lasting 48‑72 weeks. It performed even better than other popular drugs like semaglutide and tirzepatide, showing strong promise for tackling obesity and fatty‑liver disease.
Moiz. Areesha A; Filion. Kristian B KB; Toutounchi. Helia H; Tsoukas. Michael A MA; Yu. Oriana H Y O...
A review of recent trials shows that the experimental peptide retatrutide can cut body weight by about 22% after roughly a year of weekly injections, outperforming other GLP‑1 drugs like semaglutide and tirzepatide. Most side effects are stomach‑related (nausea, vomiting, diarrhea) and usually mild, though a few people stopped treatment because of them.
Stefanakis. Konstantinos K; Kokkorakis. Michail M; Mantzoros. Christos S CS
Big weight‑loss drugs like tirzepatide (and the newer retatrutide) can drop 15‑25% of body weight, but about a quarter of that loss is muscle and bone, which can hurt health, especially as you age. New drugs that block myostatin/activin (e.g., Bimagrumab, Trevogrumab, Garetosmab) may help keep muscle and bone while you lose fat, and combining them with incretin agonists could give a better body‑composition outcome.
Jakubowska. Agnieszka A; Roux. Carel W le CWL; Viljoen. Adie A
A recent phase‑2 trial tested retatrutide, a drug that hits three gut hormone receptors (GLP‑1, GIP, and glucagon). Over 48 weeks, participants taking the highest dose (12 mg) lost about 24% of their body weight, while also seeing improvements in blood sugar, cholesterol, blood pressure, inflammation, and liver fat. The study shows that hitting all three pathways at once can produce very strong weight‑loss results.
Pasqualotto. Eric E; Ferreira. Rafael Oliva Morgado ROM; Chavez. Matheus Pedrotti MP; Hohl. Alexandr...
A review of three clinical trials found that once‑weekly injections of retatrutide can cut body weight by about 10 kg (roughly 10% of body weight) and improve BMI and waist size in people who are overweight, obese, or have type‑2 diabetes. A lot more people on the drug hit big weight‑loss milestones (5%, 10%, 15% and even 20% loss) compared with placebo, though mild stomach upset and allergic‑type reactions were a bit more common.
Barton. Joshua R JR; Londregan. Annie K AK; Alexander. Tyler D TD; Entezari. Ariana A AA; Covarrubia...
This review explains how gut hormone‑producing cells (EECs) talk to the brain, and why drugs like semaglutide, terzepatide and the experimental peptide retatrutide work for weight loss and diabetes. It highlights that some EECs can send fast signals directly to nerves, and that understanding these pathways could help create better treatments for obesity and gut disorders.
Retatrutide is a new drug that hits three hormone receptors (GLP‑1, GIP, and glucagon) at once. Early animal work and Phase I‑II trials show it can cut body weight, lower blood sugar, and improve liver and kidney health, but it mainly causes stomach‑related side effects and is still being tested in larger Phase III studies.
Deravi. Maryam M; Piszczatoski. Chris C; Phillips. Bradley B; Huston. Jessica J; Vascimini. Angelina...
Retatrutide is a new drug that hits three hormone receptors (glucagon, GLP‑1, and GIP) and has shown in early trials that people can lose up to about a quarter of their body weight and shrink their waist by almost 20 cm, with the main side‑effects being stomach upset.
Ma. Jun J; Hu. Xiaoyan X; Zhang. Wencheng W; Tao. Mengyuan M; Wang. Min M; Lu. Weiping W
In a mouse study, the experimental drug retatrutide helped the animals lose more weight and protect their kidneys better than the already‑approved drugs liraglutide and tirzepatide. It also improved liver health, lowered bad cholesterol, raised good cholesterol, and boosted a gut‑derived molecule (butyrate) linked to a healthier microbiome. However, retatrutide wasn’t any better than tirzepatide at lowering blood sugar.
Al-Horani. Rami A RA; Aliter. Kholoud F KF; Aliter. Hashem F HF
The abstract reviews new drugs for diabetes and obesity, highlighting retatrutide as one of several promising treatments that could dramatically improve blood sugar control and weight loss. While it doesn’t give dosing details, it signals that retatrutide is moving through advanced trials and may become a powerful tool for people looking to manage metabolic health.
Abdul-Rahman. Toufik T; Roy. Poulami P; Ahmed. Fatma Kamal FK; Mueller-Gomez. Jann Ludwig JL; Sarkar...
Retatrutide is a new drug that hits three gut hormone receptors at once, helping people lose weight, lower blood sugar, and possibly improve heart health. Early trials (phases 1‑3) show big drops in body weight and better glucose control, but we still need more data on long‑term safety and how it works in special groups like kids.
Marathe. Sandesh J SJ; Grey. Emily W EW; Bohm. Margaret S MS; Joseph. Sydney C SC; Ramesh. Arvind V...
In mouse studies, the weight‑loss drug retatrutide not only shrank body fat but also dramatically slowed the growth of pancreatic and lung cancers linked to obesity. Even after the drug was stopped, the anti‑cancer effects stuck around, likely because it reshaped the immune system to be more anti‑tumor.
Neumann. Joachim J; Ahlrep. Undine U; Hofmann. Britt B; Gergs. Ulrich U
The study shows that retatrutide, a drug being developed for diabetes and obesity, can make human heart muscle cells contract stronger and relax faster in lab experiments. This effect comes from activating several hormone receptors that raise cAMP levels inside the cells. The findings are based on heart tissue taken from patients with severe coronary disease, not on healthy volunteers or real‑world use.